I wonder if Moderna vaccine produced ‘robust’ immune response in all patients, company says
A potential coronavirus vaccine from Moderna produced a “robust” immune response in all 45 patients in its early stage human trial, according to newly released data published in the peer-reviewed New England Journal of Medicine.
In May, the company released preliminary information from its early stage trial, but it lacked all of the data and it hadn’t been peer-reviewed yet. The newly released data provides more promising information that the vaccine may give some protection against the virus.
Earlier in the day, Moderna announced it would begin its late-stage trial for its vaccine on July 27. The trial will enroll 30,000 participants across 87 locations, according to ClinicalTrials.gov.
The effort by Moderna is one of several working toward a potential vaccine for Covid-19. More than 100 vaccines are under development globally, according to the World Health Organization. —Berkeley Lovelace Jr.